News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cellular Dynamics International, ACEA Biosciences, Inc., and Roche Applied Science Cooperate to Evaluate iCell Cardiomyocytes on the xCELLigence System


9/16/2010 9:44:02 AM

PENZBERG, Germany--(BUSINESS WIRE)--Cellular Dynamics International (CDI) announced today their partnership with ACEA Biosciences to bring early and accurate prediction of potential cardiotoxic side effects to the drug discovery process. The partnership combines CDI’s induced pluripotent stem cell (iPSC)-derived heart cells, iCell Cardiomyocytes, with the xCELLigence RTCA System. The xCELLigence System is developed by ACEA and Roche Applied Science (SIX:RO) (SIX:ROG) (Pink Sheets:RHHBY) and marketed by Roche.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES